7-[(4-bromobenzyl)oxy]-2H-chromen-2-one | 314262-36-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-[(4-bromobenzyl)oxy]-2H-chromen-2-one
• 英文别名: 7-((4-bromobenzyl)oxy)-2H-1-benzopyran-2-one；7-O-p-bromobenzyl umbelliferone；7-[(4-Bromophenyl)methoxy]chromen-2-one
• CAS: 314262-36-7
• 化学式: C₁₆H₁₁BrO₃
• mdl: MFCD02079582
• 分子量: 331.166
• InChiKey: XBQHFKZKJXERFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-[(4-bromobenzyl)oxy]-2H-chromen-2-one 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成
  参考文献：
  名称：

  Synthesis and Biological Evaluation ofortho-ArylN-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors

  摘要：

  AbstractHistone deacetylases (HDACs) are a family of enzymes that play a crucial role in biological process and diseases. In contrast to other isozymes, HDAC8 is uniquely incapable of histone acetylation. In order to delineate its physiological function, we developed HDAC8‐selective inhibitors using knowledge‐based design combined with structural modeling techniques. Enzyme inhibitory analysis demonstrated that some of the resulting compounds (22 b, 22 d, 22 f, and 22 g) exhibited anti‐HDAC8 activity superior to PCI34051, a known HDAC8‐specific inhibitor, with IC50 values in the range of 5–50 nM. Among them, compound 22 d showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1‐5); it exhibited cytotoxicity against human lung CL1‐5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR‐90 cells. Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1‐5 is higher than that in H1299 and CL1‐1 cells, a result consistent with the differential cytotoxicity of compound 22 d. These results suggest the effectiveness of our design concept, which may lead to a tool compound for studying the specific role of HDAC8 in cellular biological processes.

  DOI：

  10.1002/cmdc.201200300
• 作为产物：
  描述：

  间苯二酚 在 iron(III) chloride 、 silver trifluoromethanesulfonate 、 potassium carbonate 作用下， 以 1,2-二氯乙烷 、 乙腈 、 三氟乙酸 为溶剂， 生成 7-[(4-bromobenzyl)oxy]-2H-chromen-2-one
  参考文献：
  名称：

  苯并吡喃酮或喹啉酮类化合物及其应用

  摘要：

  本发明公开了苯并吡喃酮或喹啉酮类化合物及其在制备治疗前列腺癌药物中的应用，属于医药领域。本发明提供的结构式如式(Ⅰ)的苯并吡喃酮、喹啉酮类化合物对雄激素受体具有明显的拮抗活性，且对不表达雄激素受体的前列腺癌细胞同样具有抑制活性。因此，可将其作为雄激素受体拮抗剂应用到与雄激素受体相关的疾病治疗，或者多种转移性前列腺癌的治疗中，为治疗前列腺癌的药物开发提供新的选择。

  公开号：

  CN111533721B

文献信息

• Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease
  作者：Jacques Joubert、Germaine B. Foka、Benjamin P. Repsold、Douglas W. Oliver、Erika Kapp、Sarel F. Malan

  DOI：10.1016/j.ejmech.2016.09.041

  日期：2017.1

  A series of 7-substituted coumarin derivatives were designed and synthesised to display ChE and MAO-B inhibitory activity. The compounds consisted out of a coumarin structure (MAO-B inhibitor) and benzyl-, piperidine-, N-benzylpiperidine- or p-bromo-N-benzylpiperizine moiety, resembling the N-benzylpiperidine function of donepezil (ChE inhibitor), connected via an alkyl ether linkage at the 7 position

  设计并合成了一系列7-取代的香豆素衍生物，以显示ChE和MAO-B抑制活性。这些化合物由香豆素结构（MAO-B抑制剂）和苄基，哌啶，N-苄基哌啶-或对溴-N-苄基哌嗪部分组成，类似于多奈哌齐的N-苄基哌啶功能（ChE抑制剂），通过在7位的烷基醚键。的生物测定结果表明，所有化合物（1 - 25）显示选择性抑制到hMAO-B，历时hMAO-A，用苄氧基系列（1 - 8，10 - 13）显示出纳摩尔浓度的hMAO-B抑制作用（IC 50：0.5-73 nM）。然而，对于苄氧基系列观察到有限的ChE抑制活性，除了2，尤其是3显示出选择性的BuChE抑制外。该系列3显示出最佳的多功能活性（eqBuChE IC 50  = 0.96μM，hMAO-A IC 50  = 2.13μM，hMAO-B IC 50  = 0.0021μM）。内的Ñ苄基哌啶（16 - 19）和p溴代Ñ -benzylpiperizine（21
• Yadav, Nisha; Auti, Prashant; George, Ginson, Journal of the Indian Chemical Society, 2020, vol. 97, # 8, p. 1265 - 1271
  作者：Yadav, Nisha、Auti, Prashant、George, Ginson、Paul, Atish T.

  DOI：——

  日期：——
• Synthesis and Biological Evaluation of<i>ortho</i>-Aryl<i>N</i>-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors
  作者：Wei-Jan Huang、Yi-Ching Wang、Shi-Wei Chao、Chen-Yui Yang、Liang-Chieh Chen、Mei-Hsiang Lin、Wen-Chi Hou、Mei-Yu Chen、Tai-Lin Lee、Ping Yang、Chung-I Chang

  DOI：10.1002/cmdc.201200300

  日期：2012.10

  AbstractHistone deacetylases (HDACs) are a family of enzymes that play a crucial role in biological process and diseases. In contrast to other isozymes, HDAC8 is uniquely incapable of histone acetylation. In order to delineate its physiological function, we developed HDAC8‐selective inhibitors using knowledge‐based design combined with structural modeling techniques. Enzyme inhibitory analysis demonstrated that some of the resulting compounds (22 b, 22 d, 22 f, and 22 g) exhibited anti‐HDAC8 activity superior to PCI34051, a known HDAC8‐specific inhibitor, with IC50 values in the range of 5–50 nM. Among them, compound 22 d showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1‐5); it exhibited cytotoxicity against human lung CL1‐5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR‐90 cells. Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1‐5 is higher than that in H1299 and CL1‐1 cells, a result consistent with the differential cytotoxicity of compound 22 d. These results suggest the effectiveness of our design concept, which may lead to a tool compound for studying the specific role of HDAC8 in cellular biological processes.
• 苯并吡喃酮或喹啉酮类化合物及其应用
  申请人：浙江大学

  公开号：CN111533721B

  公开（公告）日：2022-04-26

  本发明公开了苯并吡喃酮或喹啉酮类化合物及其在制备治疗前列腺癌药物中的应用，属于医药领域。本发明提供的结构式如式(Ⅰ)的苯并吡喃酮、喹啉酮类化合物对雄激素受体具有明显的拮抗活性，且对不表达雄激素受体的前列腺癌细胞同样具有抑制活性。因此，可将其作为雄激素受体拮抗剂应用到与雄激素受体相关的疾病治疗，或者多种转移性前列腺癌的治疗中，为治疗前列腺癌的药物开发提供新的选择。